Desai et al. evaluated the presence of mutated TP53 in a normal population through prospective study, subjects that harbored a detectable VAF of 1% or more in TP53 or IDH1/2 mutation eventually developed AML. The gene discussed is TP53; the disease is acute myeloid leukemia.